20th April 2023 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has announced that Inaleucel has been added to the WHO recommended list as the international non-proprietary name (INN) oNKord®.This enables Gly
1st April, 2021 -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that Dr. Kai Pinkernell, M.D. joins Glycostem as Chief Medical Officer (CMO).
17th December, 2020 – Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer.
15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for the treatment of Acute Myeloid Leukemia (AML). The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.
20th November 2020 – Glycostem today announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
30th July, 2020 - Glycostem collaborates with LUMICKS to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population for cellular therapy.
19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered into a de
12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan